About Ventyx Biosciences, Inc. - Common Stock (VTYX)
Ventyx Biosciences Inc is a biotechnology company focused on developing innovative therapies for inflammatory and autoimmune diseases. The company harnesses its expertise in the discovery and development of small molecule drug candidates, aiming to address unmet medical needs in various conditions. By leveraging advanced scientific research and clinical insights, Ventyx seeks to bring new treatment options to patients, enhancing the quality of life for those affected by chronic inflammatory disorders. Through its ongoing research and development efforts, Ventyx aims to make significant contributions to the field of medicine. Read More
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
The Phase 2 trial showed VTX3232 cut key inflammation markers like hsCRP by about 78% and IL-6 to below risk thresholds, reinforcing its anti-inflammatory potential.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
